貝達藥業(300558.SZ):擬推1332.549萬股的2023年限制性股票激勵計劃
格隆匯11月17日丨貝達藥業(300558.SZ)公佈2023年限制性股票激勵計劃(草案),本計劃擬向激勵對象授予的第二類限制性股票數量為1332.549萬股,佔本計劃公吿時公司股本總額41,848.5885萬股的3.18%,其中:首次授予1110.549萬股,佔本計劃擬授予權益總數的83.34%,佔本計劃公吿時公司股本總額41,848.5885萬股的2.65%;預留222萬股,佔本計劃擬授予權益總數的16.66%,佔本計劃公吿時公司股本總額41,848.5885萬股的0.53%。
本激勵計劃首次授予激勵對象限制性股票的授予價格為41.17元/股,預留部分限制性股票授予價格與首次授予的限制性股票授予價格相同。
本計劃的首次授予部分激勵對象總人數為675人。預留授予部分激勵對象指本計劃獲得股東大會批准時尚未確定但在本計劃存續期間納入本激勵計劃的激勵對象,該部分激勵對象在本激勵計劃經股東大會審議通過後12個月內確定。
本激勵計劃有效期自限制性股票首次授予日起至激勵對象獲授的限制性股票全部歸屬或作廢失效之日止,最長不超過48個月。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.